CORDIS
EU research results

CORDIS

English EN

Combined Molecular Microscopy for Therapy and Personalized Medication in Rare Anaemias Treatments

Objective

The aim of CoMMiTMenT is the development of combined imaging technologies based on optofluidic microscopy and scanning ion conductance microscopy. An integrated, completely simultaneous device named µCOSMOS will be used as a proof-of-principle for therapeutic interventions in rare anaemias. Both techniques rely on molecular detection: optofluidic microscopy relies on molecular biomarkers, and scanning ion conductance microscopy on functional imaging of molecular structures. µCOSMOS allows for the exploration, diagnosis and development of therapeutic interventions for several rare anaemias, including hereditary xerocytosis, overhydrated hereditary stomatocytosis, familial pseudohyperkaliemia, cryohydrocytosis, certain types of spherocytosis, hereditary spherocytosis, sickle cell anaemia, thalassemia and phosphofructokinase deficiency.
The non-invasive nature of the combined imaging technologies, which probe the function of molecular effectors, facilitates the testing of medications and their dosage in a personalised manner. For some of the rare anaemias, CoMMiTMenT will provide an initial proof-of-principle, whereas for others, such as sickle cell anaemia, personalised medical interventions should become available and will be tested in clinical practice within the project.
CoMMiTMent will ensure an effective therapy with diminished undesirable adverse effects, largely replacing splenectomy.

CoMMiTMenT includes clinical partners and builds a strong relationship with the European Network for Rare and Congenital Anaemias (ENERCA). Furthermore, CoMMiTMenT acts as a bridge between the technology-driven SMEs and ENERCA and, as such, supports the competitiveness of Europe in this area. The applications will advance (personalised) treatment of rare anaemias and, therefore, contribute to the goal of the International Rare Diseases Research Consortium (IRDiRC) to deliver novel diagnostic modalities and 200 new therapies for rare diseases by 2020.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITAT DES SAARLANDES

Address

Campus
66123 Saarbrucken

Germany

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 051 613,76

Administrative Contact

Lars Kästner (Dr.)

Participants (9)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITAT ZURICH

Switzerland

EU Contribution

€ 580 899,57

UNIVERSITAIR MEDISCH CENTRUM UTRECHT

Netherlands

EU Contribution

€ 509 816,53

OPTOROBOTIX APS

Denmark

EU Contribution

€ 922 075,89

IONSCOPE LIMITED

United Kingdom

EU Contribution

€ 681 206,60

ARIVIS AG

Germany

EU Contribution

€ 430 080

CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER

Spain

EU Contribution

€ 410 981,68

EPIGEM LIMITED

United Kingdom

EU Contribution

€ 716 270,15

EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH

Germany

EU Contribution

€ 566 800

FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS

Spain

EU Contribution

€ 130 238,07

Project information

Grant agreement ID: 602121

Status

Closed project

  • Start date

    1 October 2013

  • End date

    30 September 2018

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 724 726,52

  • EU contribution

    € 5 999 982,25

Coordinated by:

UNIVERSITAT DES SAARLANDES

Germany

This project is featured in...